Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune diseases
Utilizing its proprietary technology, Immunovant aims to create monoclonal antibodies that target specific pathways involved in these conditions, with the goal of providing safer and more effective treatment options. The company's research and development efforts are centered on addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from autoimmune disorders. Through its commitment to scientific advancement and patient care, Immunovant actively works to bring novel treatments to the market.
Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.
With inflation and jobs behind us, it’s time to shift our focus 6,700 miles west to Tokyo. The Bank of Japan appears poised for another rate hike next week, with odds now at 77%. Monitor the VIX for early warning signals.
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves’ Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs. Finally, Immunovant also announced alignment with the U.S. Food & Drug Administration (FDA) and Investigational New Drug Application (IND) clearance with initiation of a pivotal trial of IMVT-1402 in GD expected by December 31, 2024.
